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Abstract
Objective: To prospectively examine the long-term safety of a cardiovascular health dietary supplement by
assessing a comprehensive set of safety measures.
Design: Single-arm, open-label study.
Location: National University of Natural Medicine, Portland, OR.
Subjects: Thirty adults with screening blood pressure readings consistent with prehypertension or stage I
hypertension.
Intervention: One caplet per day of a dietary supplement for 6 months. The investigated herbal–mineral
supplement contains several ingredients, most notably Rauwolfia serpentina.
Outcome measures: Primary measures included b-type natriuretic peptide (NT-proBNP), aspartate amino-
transferase (AST), alanine aminotransferase (ALT), estimated glomerular filtration rate (eGFR), electrolytes,
and the Patient Health Questionnaire (PHQ-9). Exploratory measures included physical vital signs, cholesterol
levels, high-sensitivity cardiac troponin-I, cystatin C, endothelin, interleukin (IL)-6, IL-17a, tumor necrosis
factor-a, high-sensitivity C-reactive protein, blood counts, and the Patient Reported Outcome Measure In-
formation System (PROMIS) Sleep Disturbance Short Form 8b.
Results: NT-proBNP, AST, ALT, eGFR, sodium, calcium, magnesium, PHQ-9 score, and the majority of
exploratory measures did not change. However, serum potassium increased ( p < 0.05), systolic blood pressure
decreased ( p < 0.0001), and diastolic blood pressure decreased ( p < 0.0001). There were no serious adverse
events, but 30% of participants withdrew citing potential side effects, most commonly nasal congestion or
fatigue; most participants who reported nasal congestion also reported concomitant seasonal allergies. Ad-
herence to the supplement was 90.9%.
Conclusions: The findings of this study suggest that the investigated dietary supplement is safe for long-term
use in adults with prehypertension and stage I hypertension. Additional results of this study, particularly the
increase in serum potassium and decreases in systolic and diastolic blood pressure, are promising and suggest
that future research on this dietary supplement, or its ingredients, should further explore effects on blood
pressure and biologic mechanisms of action, which may involve potassium-sparing and diuretic effects.
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Introduction
Use of dietary supplements in the United States iswidespread, with more than 166 million estimated users
and an estimated 85,000 products available.1,2 Adults with
cardiovascular disease have a particularly high prevalence
of use.3,4 An analysis of the 1999–2002 National Health
and Nutrition Examination Survey (NHANES) data showed
that 64% of respondents with hypertension took dietary
supplements.5
There is a common misperception among health care
professionals that dietary supplements are unregulated.1
However, dietary supplements are regulated in the United
States as a special category of foods by the Food and Drug
Administration (FDA) under the Dietary Supplement Health
and Education Act (DHSEA).1,2 Regulatory agencies also
exist in Canada, Europe, China, India, and Australia.2 In the
United States, dietary supplement manufacturers are not re-
quired to conduct prospective safety studies, although they
are prohibited from marketing products or using ingredients
known to be unsafe.2 Adverse events (AEs) occur with die-
tary supplements, but recent estimates indicate a relatively
low incidence, despite frequently voiced concerns regarding
dietary supplement safety.1,2 Notably, less than one death per
year has been attributed to use of dietary supplements over
the last 15 years, compared with more than 25,000 annual
deaths in the United States attributed to FDA-approved pre-
scription drugs.1
However, the limited availability of formal research on
dietary supplements creates a barrier to more widespread
clinical use. This is particularly relevant for naturopathic
physicians and other complementary medicine providers,
who frequently discuss the safety, quality, and efficacy of
dietary supplements during clinical encounters.6,7 A lack of
safety-oriented research on the tens of thousands of avail-
able dietary supplements generates both clinical and scientific
limitations, as potentially safe and efficacious supplements
may never be identified or described in peer-reviewed med-
ical literature.2 Consequently, these limitations also represent
opportunities to apply innovative early-phase study designs
to assess safety and also identify potentially efficacious die-
tary supplements.2,8,9
The authors previously reported on the naturopathic
treatment of hypertension, in which a specific Ayurvedic
herbal–mineral formula was recommended to 50.6% of the
patients.10 On subgroup analysis, use of the formula was
associated with greater reductions in blood pressure, com-
pared with those who had not been given the supplement
(unpublished data). Herbs in the formula, including Rau-
wolfia serpentina, Rosa vinca, and Convolvulus pluricaulis,
each have a long history of use in Ayurvedic management of
patients with hypertension.11–13 Also in the formula, Rosa
centifolia is commonly used in Ayurvedic formulas for in-
flammatory conditions and Tribulus terrestris, Terminalia
arjuna, and Boerhaavia diffusa each increase diuresis.14–17
Expanding on the aforementioned observational findings,
the authors designed the present study to (1) prospectively
evaluate the Ayurvedic herbal–mineral formula based on a
comprehensive set of objective safety and tolerability
measures; (2) assess patient-reported outcomes during ex-
tended use of the supplement; and (3) describe adherence
among adults with pre- and stage I hypertension.
Materials and Methods
Study design
A single-arm, open-label clinical trial designed to assess
safety and tolerability by prospectively assessing changes in
clinical laboratory biomarkers, validated questionnaires for
depression and sleep, clinical AEs, and vital signs was im-
plemented. Primary measures were defined a priori as
changes in (1) sodium, potassium, calcium, magnesium,
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), estimated glomerular filtration rate (eGFR), b-type
natriuretic peptide (NT-proBNP); and (2) Patient Health
Questionnaire (PHQ-9)-measured mood scores. Participants
were first screened for eligibility by phone and then con-
firmed with an in-person clinical screening visit. Once en-
rolled, participants returned for a baseline visit, a 3-month
midpoint visit, and a 6-month closure visit. Participants
were contacted by phone between study visits. All study-
related operations were conducted at the National University
of Natural Medicine (NUNM). This study was approved by
the Institutional Review Board at NUNM and registered at
ClincalTrials.gov (NCT02452749).
Participants and recruitment
Adults ages 18–75 years with blood pressure meeting
JNC 7 criteria for prehypertension or stage I hypertension
(120–139 mmHg systolic and/or 80–99 mmHg diastolic)
were recruited from the Portland, OR, metropolitan area.18
Target enrollment was n = 30.
Participants with the following were excluded: resting
heart rate <50 beats per minute (bpm) or <45 bpm in ath-
letes; serum sodium, potassium, or calcium levels outside of
laboratory reference ranges; elevated AST or ALT; eGFR
£60 mL/min; PHQ-9 ‡ 10; initiation of, or changes to, pre-
scription blood pressure-lowering medications or thyroid
medications within the previous month; use of b blockers, a
blockers, digoxin, levodopa, antidepressant medications,
antipsychotic medications, sedatives, tranquilizers, B. dif-
fusa, C. pluricaulis, R. serpentina, R. centifolia, R. vinca,
T. arjuna, T. terrestris, or coral powder within the previous
2 months; or participation in another interventional re-
search study within the previous month.
Participants were excluded if they had a history of
cardiovascular disease, heart surgery, cardiac arrhythmia,
pacemaker placement, abnormal electrocardiogram, abnormal
echocardiogram, kidney disease, chronic liver disease, gall-
bladder disease, bowel disease, ulcers, alcoholism, obstructive
sleep apnea, Parkinson’s disease, depression, pheochromo-
cytoma, or malignancy (within the previous 5 years); reported
consumption of more than 14 alcoholic beverages per week,
smoking or tobacco use, illicit or recreational drug use.
Lactating or pregnant women, or women planning preg-
nancy during the study period, were excluded. Also, those
with a known intolerance or allergy to ingredients in the
study supplement.
Recruitment approaches included newspaper advertise-
ments, online advertisements, and flyers. In addition, elec-
tronic health records of consenting patients of the NUNM
Health Center were queried. Potentially eligible individuals
were mailed an invitation letter and recruitment flyer on a
rolling basis.
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Study intervention
The intervention, Carditone, was a supplement manu-
factured and supplied by Ayush Herbs, Inc. (Redmond, WA)
in 60 caplet bottles. Participants were asked to take 1 caplet
nightly before bed. The supplement contains the following
ingredients in each caplet: R. centifolia, B. diffusa, and
Dendrogyra cylindrus (coral powder) as a proprietary blend
(350 mg), magnesium aspartate (200 mg), C. pluricaulis
(100 mg), T. arjuna (100 mg), T. terrestris (100 mg), low-
reserpine R. serpentina (50 mg), and R. vinca (25 mg). The
manufacturers grow the herbs in the formula on farms that
they own and process them in their plant in Nagrota Bagwan,
Himachal Pradesh, India. The supplement is manufactured in
the United States in a Good Manufacturing Practice-certified
facility. The finished supplement was analyzed for reserpine
content via high-performance liquid chromatography and
levels were below the lower limit of detection (<0.01%; In-
tertek, Champaign, IL). Lead analysis showed that levels were
<0.2 ppm (Micro Quality Labs, Inc., Burbank, CA).
Data collection
Fasting blood samples were obtained by venipuncture
by a certified phlebotomist. Vital signs were measured by
trained clinical research coordinators. Blood pressure and
resting heart rate were measured using an Omron digital
blood pressure monitor (HBP-1300) after the participant
was seated for at least 5 minutes with their back supported, feet
flat on the floor, and their arm supported at heart level.
Three consecutive readings were taken (at least 1 minute
apart) and then averaged. All questionnaires were completed
by direct interview. To assess adherence, unused study
supplement was returned for pill counts at the midpoint and
endpoint of the trial.
Clinical laboratory measures. Serum samples from the
screening visit were sent to Quest Diagnostics (Seattle, WA)
by courier the day of collection and analyzed for sodium,
potassium, calcium, AST, ALT, and eGFR to confirm eli-
gibility; however, screening laboratory values were not used
in any analyses. At subsequent visits, serum, plasma, and
whole blood were shipped to Veridia Diagnostics (Round
Rock, TX) on the day of collection and analyzed for sodium,
potassium, calcium, magnesium, NT-proBNP, AST, ALT,
eGFR, total cholesterol, low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, triglycerides, high-
sensitivity cardiac troponin-I, endothelin, cystatin C, high-
sensitivity C-reactive protein, interleukin (IL)-6, IL-17a,
tumor necrosis factor-a, white and red blood cell (RBC)
count, platelet count, hemoglobin, and hematocrit.
Participant-reported outcomes. AEs were monitored by
specific interviews during scheduled 3- and 6-month visits
and by phone calls between visits. Participants were en-
couraged to report any AE between study visits or phone
calls by contacting a clinical research coordinator or the
principal investigators. A 91-item standardized monitoring
questionnaire, developed according to the National Cancer
Institute’s Common Terminology Criteria for Adverse
Events v4.0, was administered at each trial visit. Administering
the form requires querying symptoms in eight systems: eyes/
ears/nose/throat, gastrointestinal, neurologic/musculoskeletal,
psychologic/general, cardiopulmonary, skin, genitourinary,
and constitutional systems. Symptoms are graded from 0 to
5 (0 = not present; 1 = mild [no intervention required],
2 = moderate [activities of daily living limited], 3 = severe
or medically significant, but not immediately life threat-
ening [basic self-care limited or hospitalization required],
4 = life threatening, 5 = fatal). Furthermore, AEs were classi-
fied as serious or nonserious based on FDA and Federal Food
Drug and Cosmetic Act definitions. AEs were considered
‘‘serious’’ if a participant’s outcome had included the
following: a life-threatening experience, inpatient hospitali-
zation, disability or incapacity, death, a congenital anomaly
or birth defect, or a medical or surgical intervention to
prevent one of these outcomes.19,20 All other AEs were
designated ‘‘nonserious.’’
The 9-item Patient Health Questionnaire (PHQ-9) was used
to assess changes in mood. The PHQ-9 was scored as previ-
ously described.21 An increase of >5 points was defined as a
categorical change in mood, and thus was specifically evalu-
ated at the 3- and 6-month visits. Changes in sleep quality were
assessed with the Patient Reported Outcome Measure In-
formation System (PROMIS) Sleep Disturbance Short Form
8b, which was scored as previously described.22,23
Data analysis
Continuous measures are presented as mean and standard
deviation at each time point. Changes from baseline to 3
months and from baseline to 6 months were summarized
using Glass’s Delta, a version of Cohen’s d that is computed
as the change in means divided by baseline standard devi-
ation; standardized differences are referred to as Cohen’s d
in the Results section. Significance of changes from baseline
was drawn from random intercept models applied to mea-
surements at all three time points. When outcomes showed
substantial skew or outliers, the authors conducted sensi-
tivity analyses using log transformations of the data, or
omitting outliers, as appropriate. As part of primary aims of
the study, the proportion of participants who met several a
priori defined safety and tolerability criteria at the midpoint
and trial end visits was calculated. These safety and toler-
ability criteria were as follows: NT-proBNP >400 pg/mL;
sodium, potassium, calcium, or magnesium ‡25% higher or
25% lower than the laboratory reference range; AST or
ALT >2 times the upper laboratory reference range; eGFR
decrease of ‡15 mL/min from baseline; increase in PHQ-9
score by ‡5 points (without alternative explanation); systolic
hypotension (<90 mmHg); diastolic hypotension (<60 mmHg);
systolic blood pressure increase of ‡20 mmHg compared with
baseline; diastolic blood pressure increase of ‡10 mmHg
compared with baseline; resting heart rate <50 bpm (or
<45 bpm in athletes); grade 3, 4, or 5 AEs (monitored via
the 91-item symptom monitoring form); or participant
elected to withdraw from the study citing AEs. Statistical




Baseline demographic parameters are described in
Table 1. Mean systolic and diastolic blood pressure readings
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at baseline were consistent with JNC 7 classification of
prehypertension. Flow of the study is described in Figure 1;
19 participants completed the study, 9 elected to withdraw,
1 was withdrawn by the investigators, and 1 was lost to
follow-up.
Primary measures
Significant changes in primary measures were infrequent,
both from baseline to the 3-month visit and from baseline to
the 6-month visit (Table 2). However, changes in potassium
levels were significant both from baseline to 3 months and
from baseline to 6 months ( p < 0.05). Changes in NT-
proBNP, sodium, calcium, magnesium, AST, ALT, and
eGFR were nonsignificant. Primary outcome measures plus
additional safety and tolerability criteria were also examined
as a composite (Table 3).
Adverse events
No serious AEs were reported by any participant during
the study. Nine participants (30%) elected to withdraw be-
fore completion citing nonserious AEs as the reason (Ta-
ble 4). AEs reported by 10% or more of the entire study
population included the following: lightheadedness (n = 9,
30%), nasal congestion (n = 6, 20%), feeling tired/fatigued
(n = 6, 20%), and headache (n = 3, 10%).
Exploratory measures
Significant changes in exploratory measures were more
frequent than in primary measures (Table 5). Decreases in
systolic and diastolic blood pressure were highly significant
at 3 and 6 months compared with baseline ( p < 0.0001).
Several blood measures also changed significantly, includ-
ing cystatin C, RBC count, hemoglobin, and hematocrit
( p < 0.05). However, mean values for these biomarkers re-
mained within normal laboratory reference ranges at all time
points. There were no significant changes in high-sensitivity
cardiac troponin-I, endothelin, cholesterol, inflammatory
markers, white blood cell and platelet counts, sleep ques-
tionnaire total score, or heart rate.
Study supplement adherence
A pill count of unused study supplement indicated that
adherence throughout the study was 90.9% – 11.6%.
Discussion
This trial rigorously collected long-term safety and tol-
erability data on a dietary supplement using a semipragmatic
model. The supplement evaluated has been sold in the United
States for 25 years and is recommended by naturopathic and
complementary medicine providers for cardiovascular health.
Table 1. Baseline Characteristics
of the Study Population
Mean – SD or n (%)






More than 1 race 3 (10.0)
Asian 2 (6.7)
American Indian or Alaska Native 1 (3.3)
Ethnicity
Not Hispanic or Latino 25 (83.3)
Hispanic or Latino 5 (16.7)
Body mass index (kg/m2) 28.1 – 5.4
Resting heart rate (bpm) 65.8 – 8.2
Blood pressure
Systolic (mmHg) 133.7 – 10.5
Diastolic (mmHg) 80.6 – 7.5
Taking antihypertensive medication 6 (20)
bpm, beats per minute.
FIG. 1. Study flow
diagram. AEs, adverse
events.
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Although many of the findings were unremarkable, several
findings stand out as clinically meaningful, including a lack
of serious AEs and a lack of meaningful change in many
biomarkers, including NT-proBNP, three of four electro-
lytes, liver enzymes, and eGFR. The lack of change in these
measures suggests safety and a lack of harm to major organ
systems, including the kidney, liver, and myocardium. Sig-
nificant decreases in systolic and diastolic blood pressure
were also clinically meaningful. The modest but significant
increase in serum potassium was also clinically interesting
and potentially related to modulation of blood pressure.
The decreases in blood pressure were anticipated based
on historic use of the supplement, prior research findings,
and previously reported mechanisms of action of the in-
gredients.10 These results support previously observed
findings that suggested that use of the formula was associ-
ated with clinically meaningful blood pressure reductions
when the formula was used as part of a comprehensive
Table 2. Primary Measures
Parameter
Baseline 3 months 6 months
Baseline to 3 months Baseline to 6 months
Mean – SD Mean – SD Mean – SD Cohen’s d pa Cohen’s d pa
NT-proBNP (pg/mL) 49.17 – 33.46 56.17 – 52.59 55.59 – 42.93 0.13 0.210 0.14 0.890
Sodium (mmol/L) 141.10 – 2.29 141.16 – 2.32 141.53 – 2.79 0.03 0.770 0.21 0.260
Potassium (mmol/L) 4.48 – 0.30 4.60 – 0.32 4.66 – 0.23 0.53 0.040 0.56 0.019
Calcium (mg/dL) 9.45 – 0.32 9.50 – 0.22 9.42 – 0.37 0.10 0.470 0.14 0.650
Magnesium (mg/dL) 2.12 – 0.18 2.12 – 0.18 2.13 – 0.19 0.00 0.920 -0.03 0.940
AST (U/L) 20.63 – 4.38 20.52 – 5.09 22.06 – 9.18 -0.08 0.730 0.24 0.480
ALT (U/L) 21.60 – 8.08 21.56 – 7.15 23.00 – 16.77 -0.06 0.860 0.11 0.620
eGFR (mL/min/BSA) 97.27 – 14.36 93.80 – 14.91 90.29 – 16.56 -0.10 0.380 -0.13 0.370
PHQ-9 (total score) 1.70 – 1.86 2.96 – 3.31 3.26 – 4.24 0.54 0.053 0.53 0.078
ap-Values calculated using mixed-model analysis, random intercept model.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSA, body surface area; eGFR, estimated glomerular filtration rate;
NT-proBNP, b-type natriuretic peptide; PHQ-9, Patient Health Questionnaire.
Table 3. Safety and Tolerability Criteria Composite
Parameter
3 months 6 months
Proportion Percentage Proportion Percentage
NT-proBNP >400 (pg/mL) 1 of 25 4.0 0 of 19 0.0
Sodium ‡25% higher or 25% lower than the laboratory
reference range
0 of 25 0.0 0 of 19 0.0
Potassium ‡25% higher or 25% lower than the laboratory
reference range
0 of 25 0.0 0 of 19 0.0
Calcium ‡25% higher or 25% lower than the laboratory
reference range
0 of 25 0.0 0 of 19 0.0
Magnesium ‡25% higher or 25% lower than the laboratory
reference range
0 of 25 0.0 0 of 19 0.0
AST >2 times the upper laboratory reference range 0 of 25 0.0 0 of 19 0.0
ALT >2 times the upper laboratory reference range 0 of 25 0.0 2 of 19 10.5
eGFR reduction of ‡15 mL/min/BSA from baseline 1 of 25 4.0 2 of 19 10.5
Increase in PHQ-9 score by ‡5 points (without alternative
explanation)
2 of 25 6.7 0 of 19 0.0
Systolic hypotension (<90 mmHg) 0 of 25 0.0 0 of 19 0.0
Diastolic hypotension (<60 mmHg) 0 of 25 0.0 1 of 19 5.3
Systolic blood pressure increase of ‡20 mmHg compared
with baseline
0 of 25 0.0 0 of 19 0.0
Diastolic blood pressure increase of ‡10 mmHg compared
with baseline
1 of 25 4.0 0 of 19 0.0
Resting heart rate <50 bpm (or <45 bpm in athletes) 0 of 25 0.0 1 of 19 5.3
New-onset moderate or greater severity dizziness 0 of 25 0.0 0 of 19 0.0
Grade 3, 4, or 5 adverse events 0 of 30 0.0 0 of 25 0.0
Withdrew from the study citing adverse effects 5 of 30 16.7 4 of 25 16.0
Composite 9a of 30 30.0 10 of 25 40.0
aAt the midpoint visit, nine participants met at least one of these criteria. One participant had both elevated NT-proBNP and an increase
in diastolic blood pressure of ‡10 mmHg compared with baseline. These adverse changes were attributable to a new prescription medication
(gabapentin prescribed after baseline) and inadvertently doubling supplemental niacin the morning of the study visit. This individual was
withdrawn as a precautionary measure. Their NT-Pro-BNP was repeated after withdrawal and had returned to within-normal limits. Their
NT-proBNP data were excluded from the analysis.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSA, body surface area; bpm, beats per minute; eGFR, estimated
glomerular filtration rate; NT-proBNP, b-type natriuretic peptide; PHQ-9, Patient Health Questionnaire.
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naturopathic treatment plan to address hypertension. Re-
garding potential mechanisms of action of the formula
studied, R. serpentina is rich in alkaloids that exhibit mul-
tiple pharmacologic actions, including a vasodilatory ef-
fect and alteration of the balance between the sympathetic
and parasympathetic nervous systems.24 R. vinca contains
alkaloids that act as a-adrenergic receptor antagonists.12
T. terrestris, T. arjuna, and B. diffusa each increases di-
uresis.15–17 T. terrestris and B. diffusa also each inhibit
angiotensin-converting enzyme (ACE) activity.17,25
The observed increase in potassium was unexpected,
since modulation of serum potassium was not a previously
known clinical effect of the formula. However, the increase
in potassium is consistent with previously reported pre-
clinical data on ingredients in the formula; T. arjuna and
T. terrestris have each been shown to increase potassium,
along with diuresis, in animal models.15,16 Furthermore,
the increase in serum potassium could have been related to
potential inhibition of ACE activity by T. terrestris and
B. diffusa.17,25 It is well documented that agents that inhibit
ACE have the downstream effect of reducing renal potas-
sium excretion.26 However, this study was not designed to
assess ACE activity.
Interestingly, mean cystatin C increased throughout the
study, yet remained within the normal laboratory reference
range. Cystatin C is a biomarker of glomerular filtration and





Nasal congestion 3 History of seasonal allergies noted in two of the three individuals;
a third participant commented that wildfires (causing diminished local
air quality) may have contributed to their symptoms
Felt tired/fatigued 3
Sleep disturbance 2 One participant reported sleep disturbance due to nasal congestion;
another participant reported insomnia and graphic dreams
Hypotension (self-report) 1 Was on concomitant antihypertensive medication
Lightheadedness, mild 1
Headaches 1 Worsening of preexisting symptom
Feeling depressed
and unmotivated
1 Most attributable to several personal adjustment issues
Twelve total signs/symptoms were reported by nine participants who elected to withdraw. One participant who reported nasal congestion
(with concomitant seasonal allergies) also reported sleep disturbance. Another participant with nasal congestion (and seasonal allergies)
also reported feeling tired/fatigued. The participant who reported mild light-headedness also reported worsening of preexisting headaches.
Table 5. Exploratory Measures
Parameter





Mean – SD Mean – SD Mean – SD Cohen’s d pa Cohen’s d pa
Cardiac troponin-I (pg/mL) 1.03 – 0.66 0.98 – 0.63 1.09 – 0.59 -0.10 0.550 0.04 0.600
Endothelin (pg/mL) 2.16 – 0.55 2.25 – 0.66 2.05 – 0.37 0.11 0.520 -0.20 0.390
Total cholesterol (mg/dL) 198.63 – 37.34 199.84 – 36.14 203.29 – 32.27 0.05 0.610 -0.14 0.580
LDL (mg/dL) 129.30 – 35.64 131.64 – 35.51 129.00 – 31.88 0.06 0.480 -0.21 0.140
HDL (mg/dL) 55.27 – 12.74 54.52 – 13.64 56.88 – 15.26 0.03 0.720 0.06 0.600
Triglycerides (mg/dL) 117.43 – 53.64 115.92 – 57.41 124.82 – 73.83 -0.01 0.750 -0.13 0.680
hs-CRP (mg/L) 1.46 – 1.62 1.42 – 1.30 2.80 – 5.38 -0.05 0.940 0.60 0.140
Interleukin-6 (pg/mL) 0.94 – 0.59 1.13 – 0.81 0.88 – 0.34 0.26 0.170 -0.13 0.900
Interleukin-17A (pg/mL) 0.47 – 0.29 0.73 – 0.96 0.48 – 0.26 0.73 0.160 -0.31 0.720
Tumor necrosis factor-a (pg/mL) 2.05 – 0.75 1.98 – 0.65 1.92 – 0.56 -0.16 0.360 -0.17 0.390
Cystatin C (mg/L) 0.82 – 0.14 0.87 – 0.14 0.93 – 0.16 0.24 0.010 0.40 0.001
White blood cell count
(thousand/mL)
5.58 – 1.08 5.50 – 1.24 5.18 – 0.88 0.04 0.810 -0.20 0.270
Red blood cell count (million/mL) 4.79 – 0.39 4.77 – 0.42 4.64 – 0.36 -0.06 0.540 -0.24 0.030
Hemoglobin (g/dL) 14.35 – 0.79 14.19 – 0.94 14.04 – 0.80 -0.21 0.100 -0.34 0.010
Hematocrit (%) 43.88 – 2.72 43.39 – 2.75 42.67 – 2.61 -0.18 0.180 -0.34 0.010
Platelet count (thousand/mL) 223.17 – 58.33 213.04 – 62.79 190.58 – 46.66 -0.01 0.890 -0.21 0.120
PROMIS sleep disturbance
total score
16.43 – 5.00 17.84 – 7.08 16.11 – 5.58 0.36 0.160 -0.08 0.950
Heart rate (bpm) 65.80 – 8.21 63.68 – 21.08 58.11 – 6.75 -0.19 0.645 -0.69 0.134
Systolic blood pressure (mmHg) 133.73 – 10.47 119.28 – 11.75 120.11 – 8.70 -1.59 <0.0001 -1.58 <0.0001
Diastolic blood pressure (mmHg) 80.60 – 7.54 71.56 – 7.59 71.16 – 7.42 -1.22 <0.0001 -1.19 <0.0001
ap-Values calculated using mixed-model analysis, random intercept model.
bpm, beats per minute; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein;
PROMIS, Patient Reported Outcome Measure Information System.
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unlike eGFR, which is an estimate of glomerular filtration
rate, cystatin C is independent from serum creatinine, age,
gender, race, and muscle mass.27,28 Since cystatin C is
highly sensitive to change in glomerular filtration rate, the
slight increase in serum cystatin C is plausibly related to
increased urine output (diuresis), if the supplement did in-
deed increase diuresis.28 However, this study was not de-
signed to assess urine output.
This analysis also demonstrated small but significant
decreases in RBC count, hemoglobin, and hematocrit over
the course of the study. Epidemiologic data collected from
racially diverse populations in multiple studies demon-
strated that RBC count, hemoglobin, and hematocrit are
each highly correlated with both systolic and diastolic blood
pressure.29–32 Hematocrit in particular is the prevailing de-
terminant of blood viscosity and as a result plays a role in
long-term modulation of blood pressure.29,33 It is plausible
that the slight decreases in RBC count, hemoglobin, and
hematocrit observed after 6 months are related to the de-
creases in systolic and diastolic blood pressure demonstrated
in the first 3 months of the study.
Although there were no serious AEs, 30% of the study
sample elected to withdraw due to nonserious AEs. The non-
serious AEs reported by 10% or more of the entire study
population were not surprising given previously published
clinical data. The mild and typically transient light-headedness
reported was most likely related to the observed change in
systolic and diastolic blood pressure. Many agents, particularly
antihypertensives, can cause dizziness.34 Nasal congestion is a
well-known effects of R. serpentina.11 A long-term study on
the effect of R. serpentina extract in hypertensive individuals
published in 1956 reported nasal congestion in 30% of par-
ticipants.35 In the present study, 20% of participants reported
nasal congestion. All but one individual who reported nasal
congestion also reported preexisting seasonal allergies, sug-
gesting that seasonal allergies may be a contraindication for
some individuals. R. serpentina is also known to cause fatigue
and T. arjuna has been reported to cause headache.24,36
This study has both strengths and limitations. Strengths
include successful implementation of a robust experimental
design, devised to collect long-term and comprehensive data
on an herbal–mineral formula not previously evaluated in a
prospective clinical study. An additional strength was ex-
cellent adherence by the participants as demonstrated by pill
count data. While not including a control group may be
perceived as a limitation, an early-phase study does not al-
ways require an untreated group according to Aickin, con-
sidering that the real purpose of early-phase research is to
inform and influence future research effort.8 Carefully de-
signed single-group studies can suffice depending on the
response of participants.8 A clinically relevant limitation of
the study was evaluating one dosage of the dietary supple-
ment. The authors investigated a dosage of one caplet per
day, but health care providers who recommend the supple-
ment will sometimes suggest a dosage regimen of up to four
caplets per day, based on the clinical presentation of each
patient. The high rate of withdrawal from the study was also
an important limitation, especially in a study with a rela-
tively small number of participants. The high rate of with-
drawal was partly a reflection of the study design, which
collected data from participants over a 6-month period, a
lengthy time frame for a dietary supplement study.
A randomized, placebo-controlled trial for the treatment of
hypertension is justified to confirm and expand on the clini-
cally meaningful decreases in systolic and diastolic blood
pressure observed in the present study. It is plausible that the
changes in potassium and blood pressure are related, and thus,
future research should explore if the mechanisms involve
potassium-sparing and diuretic effects. In the meantime, the
results presented here greatly inform the clinical community
about what to expect from the use of this dietary supplement in
practice, including rates of clinically relevant AEs, reasons for
potential limitations in adherence, the expected magnitude of
blood pressure decreases at a typical starting dosage, and
cautions of potential interactions with other agents, including
prescription potassium-sparing diuretics.
Conclusions
The findings of this study suggest that the investigated
dietary supplement is safe for long-term use in adults with
prehypertension and stage I hypertension. Additional results
of this study, particularly the decreases in systolic and dia-
stolic blood pressure, and the potentially related increase in
serum potassium, can also serve to inform future clinical
research endeavors that explore efficacy and mechanisms of
action of the investigated dietary supplement or its ingre-
dients. A follow-up study, that includes a control arm and
tests additional dosages of the supplement, is justified to
expand on the findings of this study.
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